Taux relatifs de rémission et de faible activité de la maladie du tofacitinib, du baricitinib, de l'upadacitinib et du filgotinib versus méthotrexate chez des patients atteints de polyarthrite rhumatoïde sans antirhumatismal modificateur de la maladie
Pharmacology 2023;108(6):589–598 doi 10.1159/000527186
The results of a Bayesian network meta-analysis by Lee and Song showed that JAK inhibitors were more likely to achieve remission and LDA in DMARD-naive RA patients than MTX. However, there were no significant differences in remission rates nor LDA rates between the JAK inhibitors investigated.
This meta-analysis included four RCTs that captures remission (DAS28-CRP<2.6) and LDA (DAS28-CRP≤3.2) rates resulting from treatment with tofacitinib, baricitinib, upadacitinib, and filgotinib monotherapy, versus MTX in patients with DMARD-naive RA.
